Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BioHarvest Sciences ( (BHST) ) has provided an update.
BioHarvest Sciences Inc. announced it will disclose its third-quarter financial results for 2025 on November 13, followed by an investor conference call and webcast. This announcement is significant for stakeholders as it provides insights into the company’s financial health and strategic direction, potentially impacting its market positioning and investor confidence.
The most recent analyst rating on (BHST) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on BioHarvest Sciences stock, see the BHST Stock Forecast page.
Spark’s Take on BHST Stock
According to Spark, TipRanks’ AI Analyst, BHST is a Neutral.
BioHarvest Sciences faces significant financial challenges, with high leverage and negative equity impacting its long-term sustainability. While technical indicators show some positive momentum, the valuation remains unattractive due to ongoing losses. The earnings call provided a positive outlook with strong revenue growth and strategic initiatives, but increased expenses and net losses remain concerns.
To see Spark’s full report on BHST stock, click here.
More about BioHarvest Sciences
BioHarvest Sciences Inc. is a leader in Botanical Synthesis, utilizing its patented technology platform to produce plant-based compounds without cultivating the actual plants. The company operates in two main business areas: as a contract development and production organization (CDMO) for clients needing complex molecules, and as a developer of proprietary nutraceutical health and wellness products, including dietary supplements.
Average Trading Volume: 61,315
Technical Sentiment Signal: Buy
Current Market Cap: $181.2M
See more data about BHST stock on TipRanks’ Stock Analysis page.